Atlantic Healthcare granted U.S. patent extending IP cover of alicaforsen in the treatment of inflammatory bowel disease


Patent covers use of antisense oligonucleotides to treat rectal stump inflammation and painCambridge, UK; November 7, 2016. Atlantic Healthcare plc ("Atlantic Healthcare"), an emerging trans-Atlantic pharmaceutical company with a core focus on…

Read More

Atlantic Healthcare a finalist for the pharma industry 2016 Scrip Awards


Cambridge, UK; September 29, 2016. Atlantic Healthcare plc ("Atlantic Healthcare"), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI) disorders, announces that is a finalist in the 12th Annual…

Read More

Atlantic Healthcare progresses manufacturing arrangements for globalsupply of alicaforsen


Atlantic Healthcare appoints Mike Webb as Vice President of Manufacturing and partners with Avecia for commercial supply Cambridge, UK; June 30, 2016. Atlantic Healthcare plc ("Atlantic Healthcare"), an international specialty pharma company with a…

Read More

Atlantic Healthcare closes $24 million financing with founders of SalixPharmaceuticals and Clinigen Group, and LDC


Investment secures funds to complete pivotal Phase 3 trial of alicaforsen in pouchitis and file for regulatory approval in North America and Europe Dr Lorin K Johnson, Scientific Founder of Salix Pharmaceutical, joins Board and Leadership team…

Read More

Atlantic Healthcare starts pivotal Phase 3 trial of Alicaforsen to treatInflammatory Bowel Disease Pouchitis


Study of fast-tracked and orphan designated alicaforsen is the largest ever in pouchitis, and aims to confirm efficacy in antibiotic refractory patientsCambridge, UK, 11 February 2016. Atlantic Healthcare plc, ("Atlantic Healthcare") an…

Read More